As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Medicilon chemistry provides customers with a variety of contract options depending on their specific project requirements. The choice of contract options depends on the complexity of the project, the volume of work to be conducted and the client’s level of comfort with Medicilon.
Our Chemistry department owns the professional chemical synthesis techniques. We have a good track record of producing preclinical drug candidates.
Time & Materials
Medicilon provides an estimated cost for the project.
The client pays only for actual time spent and materials used.
This model is more appropriate than Fixed Bid for projects with speculative chemistry.
All IP is owned by the client.
For clients with a small volume of work to outsource, projects are usually best handled on a Fixed Bid or Time & Materials basis, depending on project complexity.
For larger collaborations, clients normally prefer to develop a relationship by starting with Fixed Bid and/or Time & Materials contracts, as appropriate. This provides a low-risk mechanism for clients to evaluate our performance prior to moving into the more intimate and cost-effective Full-Time Equivalent (FTE) relationship.
In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.
Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models. Medicilon FTE/FFS service scope covers medicinal chemistry, synthetic chemistry, analytical chemistry.
Full-Time Equivalent (FTE)
The client contracts for one or more Medicilon chemists to work on its projects full-time.
The client is invoiced quarterly for the contracted amount, plus project-specific raw materials.
All IP is owned by the client.
This model provides reliable capacity, since the chemist(s) is devoted to the client.
It also provides maximum flexibility and efficiency, since client direction changes can be made at any time without reissuing purchase orders or revising contracts.
Finally, it provides minimum response time to new requests, since no quotes, purchase orders or negotiations are required.
Custom chemistry: 12 years experience in delivering marker compounds, published or novel samples up to 50g scale.
Chemical libraries: 12 years experience in parallel chemistry, design of efficient library schemes. One of the most experienced library provider teams in Europe having delivered > 800 custom requested libraries to our partners.
Medicinal chemistry: Our team incorporates both biotech and big Pharma expertise in lead optimization. Combination of our level of expertise with our low medicinal chemistry FTE rate makes ComInnex the most cost effective medicinal chemistry provider in the EU offering an unbeatable value to its partners.
Analytical Chemistry:Chemical Analytical Center of Medicilon provides general analysis and purification services for the clients. Our experts have rich experience and proficient skills to solve problems. We are highly appreciated by the clients.
Contact US
Email:marketing@medicilon.com
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon's Chemistry Research